A.R.T. Advisors’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

A.R.T. Advisors’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-9,324	Closed	-$527K	–	1803
2019 Q3	$527K	Buy	+9,324	New	+$524K	0.03%	838
2017 Q4	–	Sell	-12,000	Closed	-$715K	–	1728
2017 Q3	$715K	Buy	+12,000	New	+$726K	0.04%	692
2016 Q3	–	Sell	-84,039	Closed	-$3.26M	–	1226
2016 Q2	$3.26M	Buy	+84,039	New	+$3.5M	0.16%	164
2015 Q3	–	Sell	-47,560	Closed	-$3.85M	–	1649
2015 Q2	$3.85M	Sell	47,560 -21,142	-31%	-$1.38M	0.13%	220
2015 Q1	$2.88M	Buy	+68,702	New	+$1.95M	0.1%	273

Other funds holding EGRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

A.R.T. Advisors's EGRX Position: Q4 2019 in Review

A.R.T. Advisors sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2019, closing a stake of 9,324 shares — an estimated $527K sold.

A.R.T. Advisors first reported a position in EGRX in Q1 2015 and held it in 5 quarters. The position peaked at $3.85M in Q2 2015. 176 funds tracked by Wall St. Rank hold EGRX as of Q4 2019.

A.R.T. Advisors reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2019 after selling out during the quarter.
A.R.T. Advisors sold 9,324 Eagle Pharmaceuticals, Inc. shares in Q4 2019, an estimated $527K.
A.R.T. Advisors first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2015 and held it in 5 quarters.
A.R.T. Advisors's Eagle Pharmaceuticals, Inc. position peaked at $3.85M in Q2 2015.
176 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2019.

Based on A.R.T. Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.